After two decades of policy focus, China has big advantages. But the U.S. still has ways to get in on the Africa game
Coca-Cola’s North America president, Sandy Douglas, oversees a relaunch of America’s No. 1 soft drink
New rules are intended to encourage federal contractors to settle, rather than risk violations that can cost them government work
How will strapping on Google Glass or a smart watch when you're at work affect privacy and productivity?
Lisbon is not Paris. But Portuguese taxes have their allure
The drab choking poster is getting a makeover by artists, whether it needs it or not
Women are increasingly downing hard alcohol at work events. So what should you order? A female bartender creates the perfect networking cocktail
According to a business school professor with years of research in negotiation bias toward women, flirting can't be ruled out as a strategy
The historic house called Stetson Mansion gets top marks on TripAdvisor
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."